Thermo Fisher Scientific (TMO) is poised to be a strong presence in the biotech market according to various analysts' perspectives. The firm's stock has consistently outperformed the market, thanks in part to a recently secured
$1 billion Vaccine Manufacturing Pact with Vaxcyte. Beyond that, notable expansions include a strategic partnership with
AstraZeneca BioVentureHub for Research and Development initiatives. There is palpable market optimism about the company's strategic moves. Meanwhile, Barclays maintains a
Buy rating on TMO and has raised its target price to $585, further strengthening its potential in the market. Additionally, Thermo Fisher's recent strategic deals have offered new valuation insights and have been linked to a significant uptick in U.S. Expansion strategies. The company's performance in Q2 was also seen as a drag according to industry commenters. Besides these, TMO has also completed its acquisition of
Sanofi’s Ridgefield, New Jersey Site as well as Solventum’s
Purification & Filtration business. It has also been making waves with its latest product launches and distribution deals.
Thermo Fisher Scientific TMO News Analytics from Fri, 28 Mar 2025 07:00:00 GMT to Sat, 04 Oct 2025 21:01:52 GMT -
Rating 8
- Innovation 6
- Information 7
- Rumor -3
